Boston Commerce Limited has scheduled a meeting of its Board of Directors on Saturday, May 30, 2026, to consider and approve the audited standalone financial results for the quarter and year ended March 31, 2026. The meeting will be held pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board will review the financial performance for the fourth quarter and the full fiscal year. In addition to the financial results, the directors will consider any other matter with the permission of the Chair.

In accordance with the company's code of conduct for the prevention of insider trading, the trading window for designated persons remains closed. The window initially closed on April 1, 2026, and will remain shut until 48 hours after the results are declared and made public following the Board meeting.

Key Meeting Details

The company, formerly known as Boston Bio Systems Limited, has communicated the meeting details to the stock exchanges. The intimation was signed by Ghanshyam Dhananjay Gavali, Managing Director.

Boston bio systems ltd. has officially completed its corporate name change to Boston Commerce Limited, with the new identity taking effect from February 20, 2026. The transformation marks a significant rebranding initiative for the Gujarat-based company, which maintains its operations from its registered office at A.828, Sun West Bank, Ashram Road, Ahmedabad.

Regulatory Approvals and Implementation

The name change received comprehensive regulatory approval from multiple authorities. The BSE acknowledged and approved the corporate name modification, ensuring seamless transition for trading operations. The Ministry of Corporate Affairs issued a fresh Certificate of Incorporation on November 27, 2025, formally recognizing the name change from Boston Bio Systems Limited to Boston Commerce Limited.

Trading and Market Impact

The BSE issued Notice No. 20260216-37 on February 16, 2026, informing trading members about the corporate name change. The exchange confirmed that the scrip code 531458 remains unchanged, ensuring continuity for investors and market participants. The BOLT Plus System will reflect the updated company name while maintaining the abbreviated name "BOSTON" for trading purposes.

Legal and Corporate Continuity

Managing Director Ghanshyam Dhananjay Gavali emphasized that the name change does not affect the company's legal status or obligations. The Corporate Identification Number and other legal identities remain intact, ensuring all existing contracts, agreements, and stakeholder relationships continue without disruption.

The Certificate of Incorporation reveals the company's corporate evolution, noting it was originally incorporated as Adhyatmdeep Eye Foundation Limited before becoming Boston Bio Systems Limited, and now transitioning to Boston Commerce Limited. This progression reflects the company's strategic repositioning in the market.

Compliance and Disclosure Requirements

The company fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. As per regulatory requirements, the company must display both the old and new names for two years at all locations where the company name is required to be displayed under Section 12 of the Companies Act.

Stakeholders can verify the company's updated status and access public documents through the Ministry of Corporate Affairs website at www.mca.gov.in/MCA21 . The company continues to operate its website at www.bostonbio.in and maintains its email communication at bostonsystem@yahoo.com during the transition period.